Global Antidiabetic Glucagon-like Peptide 1 Agonists Supply, Demand and Key Producers, 2024-2030

Description

The global Antidiabetic Glucagon-like Peptide 1 Agonists market size is expected to reach $ 7350.8 million by 2030, rising at a market growth of 4.1% CAGR during the forecast period (2024-2030).

The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

This report studies the global Antidiabetic Glucagon-like Peptide 1 Agonists production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Antidiabetic Glucagon-like Peptide 1 Agonists, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antidiabetic Glucagon-like Peptide 1 Agonists that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Antidiabetic Glucagon-like Peptide 1 Agonists total production and demand, 2019-2030, (K Units)
Global Antidiabetic Glucagon-like Peptide 1 Agonists total production value, 2019-2030, (USD Million)
Global Antidiabetic Glucagon-like Peptide 1 Agonists production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Antidiabetic Glucagon-like Peptide 1 Agonists consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Antidiabetic Glucagon-like Peptide 1 Agonists domestic production, consumption, key domestic manufacturers and share
Global Antidiabetic Glucagon-like Peptide 1 Agonists production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Antidiabetic Glucagon-like Peptide 1 Agonists production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Antidiabetic Glucagon-like Peptide 1 Agonists production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).

This reports profiles key players in the global Antidiabetic Glucagon-like Peptide 1 Agonists market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb and Abbott Laboratories, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Antidiabetic Glucagon-like Peptide 1 Agonists market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market, Segmentation by Type
    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market, Segmentation by Application
    Hospital
    Pharmacy

Companies Profiled:
    Novo Nordisk
    AstraZeneca
    Eli Lily
    GSK
    Sanofi
    Bristol-Myers Squibb
    Abbott Laboratories

Key Questions Answered
1. How big is the global Antidiabetic Glucagon-like Peptide 1 Agonists market?
2. What is the demand of the global Antidiabetic Glucagon-like Peptide 1 Agonists market?
3. What is the year over year growth of the global Antidiabetic Glucagon-like Peptide 1 Agonists market?
4. What is the production and production value of the global Antidiabetic Glucagon-like Peptide 1 Agonists market?
5. Who are the key producers in the global Antidiabetic Glucagon-like Peptide 1 Agonists market?

Table of Contents

1 Supply Summary
    1.1 Antidiabetic Glucagon-like Peptide 1 Agonists Introduction
    1.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Supply & Forecast
        1.2.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value (2019 & 2023 & 2030)
        1.2.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030)
        1.2.3 World Antidiabetic Glucagon-like Peptide 1 Agonists Pricing Trends (2019-2030)
    1.3 World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Region (Based on Production Site)
        1.3.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Region (2019-2030)
        1.3.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Region (2019-2030)
        1.3.3 World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2019-2030)
        1.3.4 North America Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030)
        1.3.5 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030)
        1.3.6 China Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030)
        1.3.7 Japan Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Antidiabetic Glucagon-like Peptide 1 Agonists Major Market Trends

2 Demand Summary
    2.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Demand (2019-2030)
    2.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption by Region
        2.2.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption by Region (2019-2024)
        2.2.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Forecast by Region (2025-2030)
    2.3 United States Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030)
    2.4 China Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030)
    2.5 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030)
    2.6 Japan Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030)
    2.7 South Korea Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030)
    2.8 ASEAN Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030)
    2.9 India Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030)

3 World Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers Competitive Analysis
    3.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Manufacturer (2019-2024)
    3.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Manufacturer (2019-2024)
    3.3 World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturer (2019-2024)
    3.4 Antidiabetic Glucagon-like Peptide 1 Agonists Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Antidiabetic Glucagon-like Peptide 1 Agonists in 2023
        3.5.3 Global Concentration Ratios (CR8) for Antidiabetic Glucagon-like Peptide 1 Agonists in 2023
    3.6 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Overall Company Footprint Analysis
        3.6.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Region Footprint
        3.6.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Type Footprint
        3.6.3 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Comparison
        4.1.1 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Comparison (2019 & 2023 & 2030)
        4.1.2 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Comparison
        4.2.1 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Comparison
        4.3.1 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Comparison (2019 & 2023 & 2030)
        4.3.2 United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Market Share Comparison (2019 & 2023 & 2030)
    4.4 United States Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers and Market Share, 2019-2024
        4.4.1 United States Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value (2019-2024)
        4.4.3 United States Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2024)
    4.5 China Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers and Market Share
        4.5.1 China Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value (2019-2024)
        4.5.3 China Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2024)
    4.6 Rest of World Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers and Market Share, 2019-2024
        4.6.1 Rest of World Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value (2019-2024)
        4.6.3 Rest of World Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2024)

5 Market Analysis by Type
    5.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Exenatied
        5.2.2 Liraglutide
        5.2.3 Lixisenatide
        5.2.4 Albiglutide
        5.2.5 Dulaglutide
    5.3 Market Segment by Type
        5.3.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Type (2019-2030)
        5.3.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Type (2019-2030)
        5.3.3 World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Pharmacy
    6.3 Market Segment by Application
        6.3.1 World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Application (2019-2030)
        6.3.2 World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Application (2019-2030)
        6.3.3 World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2019-2030)

7 Company Profiles
    7.1 Novo Nordisk
        7.1.1 Novo Nordisk Details
        7.1.2 Novo Nordisk Major Business
        7.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        7.1.4 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.1.5 Novo Nordisk Recent Developments/Updates
        7.1.6 Novo Nordisk Competitive Strengths & Weaknesses
    7.2 AstraZeneca
        7.2.1 AstraZeneca Details
        7.2.2 AstraZeneca Major Business
        7.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        7.2.4 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.2.5 AstraZeneca Recent Developments/Updates
        7.2.6 AstraZeneca Competitive Strengths & Weaknesses
    7.3 Eli Lily
        7.3.1 Eli Lily Details
        7.3.2 Eli Lily Major Business
        7.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        7.3.4 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.3.5 Eli Lily Recent Developments/Updates
        7.3.6 Eli Lily Competitive Strengths & Weaknesses
    7.4 GSK
        7.4.1 GSK Details
        7.4.2 GSK Major Business
        7.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        7.4.4 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.4.5 GSK Recent Developments/Updates
        7.4.6 GSK Competitive Strengths & Weaknesses
    7.5 Sanofi
        7.5.1 Sanofi Details
        7.5.2 Sanofi Major Business
        7.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        7.5.4 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.5.5 Sanofi Recent Developments/Updates
        7.5.6 Sanofi Competitive Strengths & Weaknesses
    7.6 Bristol-Myers Squibb
        7.6.1 Bristol-Myers Squibb Details
        7.6.2 Bristol-Myers Squibb Major Business
        7.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        7.6.4 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.6.5 Bristol-Myers Squibb Recent Developments/Updates
        7.6.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
    7.7 Abbott Laboratories
        7.7.1 Abbott Laboratories Details
        7.7.2 Abbott Laboratories Major Business
        7.7.3 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        7.7.4 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.7.5 Abbott Laboratories Recent Developments/Updates
        7.7.6 Abbott Laboratories Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Antidiabetic Glucagon-like Peptide 1 Agonists Industry Chain
    8.2 Antidiabetic Glucagon-like Peptide 1 Agonists Upstream Analysis
        8.2.1 Antidiabetic Glucagon-like Peptide 1 Agonists Core Raw Materials
        8.2.2 Main Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Antidiabetic Glucagon-like Peptide 1 Agonists Production Mode
    8.6 Antidiabetic Glucagon-like Peptide 1 Agonists Procurement Model
    8.7 Antidiabetic Glucagon-like Peptide 1 Agonists Industry Sales Model and Sales Channels
        8.7.1 Antidiabetic Glucagon-like Peptide 1 Agonists Sales Model
        8.7.2 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Region (2019, 2023 and 2030) & (USD Million)
    Table 2. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Region (2019-2024) & (USD Million)
    Table 3. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Region (2025-2030) & (USD Million)
    Table 4. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share by Region (2019-2024)
    Table 5. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share by Region (2025-2030)
    Table 6. World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Region (2019-2024) & (K Units)
    Table 7. World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Region (2025-2030) & (K Units)
    Table 8. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share by Region (2019-2024)
    Table 9. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share by Region (2025-2030)
    Table 10. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2019-2024) & (US$/Unit)
    Table 11. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2025-2030) & (US$/Unit)
    Table 12. Antidiabetic Glucagon-like Peptide 1 Agonists Major Market Trends
    Table 13. World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
    Table 14. World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption by Region (2019-2024) & (K Units)
    Table 15. World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Forecast by Region (2025-2030) & (K Units)
    Table 16. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Manufacturer (2019-2024) & (USD Million)
    Table 17. Production Value Market Share of Key Antidiabetic Glucagon-like Peptide 1 Agonists Producers in 2023
    Table 18. World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Manufacturer (2019-2024) & (K Units)
    Table 19. Production Market Share of Key Antidiabetic Glucagon-like Peptide 1 Agonists Producers in 2023
    Table 20. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 21. Global Antidiabetic Glucagon-like Peptide 1 Agonists Company Evaluation Quadrant
    Table 22. World Antidiabetic Glucagon-like Peptide 1 Agonists Industry Rank of Major Manufacturers, Based on Production Value in 2023
    Table 23. Head Office and Antidiabetic Glucagon-like Peptide 1 Agonists Production Site of Key Manufacturer
    Table 24. Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Type Footprint
    Table 25. Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Application Footprint
    Table 26. Antidiabetic Glucagon-like Peptide 1 Agonists Competitive Factors
    Table 27. Antidiabetic Glucagon-like Peptide 1 Agonists New Entrant and Capacity Expansion Plans
    Table 28. Antidiabetic Glucagon-like Peptide 1 Agonists Mergers & Acquisitions Activity
    Table 29. United States VS China Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 30. United States VS China Antidiabetic Glucagon-like Peptide 1 Agonists Production Comparison, (2019 & 2023 & 2030) & (K Units)
    Table 31. United States VS China Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
    Table 32. United States Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value, (2019-2024) & (USD Million)
    Table 34. United States Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share (2019-2024)
    Table 35. United States Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2024) & (K Units)
    Table 36. United States Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share (2019-2024)
    Table 37. China Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value, (2019-2024) & (USD Million)
    Table 39. China Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share (2019-2024)
    Table 40. China Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2024) & (K Units)
    Table 41. China Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share (2019-2024)
    Table 42. Rest of World Based Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value, (2019-2024) & (USD Million)
    Table 44. Rest of World Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share (2019-2024)
    Table 45. Rest of World Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2024) & (K Units)
    Table 46. Rest of World Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share (2019-2024)
    Table 47. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 48. World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Type (2019-2024) & (K Units)
    Table 49. World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Type (2025-2030) & (K Units)
    Table 50. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Type (2019-2024) & (USD Million)
    Table 51. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Type (2025-2030) & (USD Million)
    Table 52. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2019-2024) & (US$/Unit)
    Table 53. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2025-2030) & (US$/Unit)
    Table 54. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 55. World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Application (2019-2024) & (K Units)
    Table 56. World Antidiabetic Glucagon-like Peptide 1 Agonists Production by Application (2025-2030) & (K Units)
    Table 57. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Application (2019-2024) & (USD Million)
    Table 58. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Application (2025-2030) & (USD Million)
    Table 59. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2019-2024) & (US$/Unit)
    Table 60. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2025-2030) & (US$/Unit)
    Table 61. Novo Nordisk Basic Information, Manufacturing Base and Competitors
    Table 62. Novo Nordisk Major Business
    Table 63. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 64. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 65. Novo Nordisk Recent Developments/Updates
    Table 66. Novo Nordisk Competitive Strengths & Weaknesses
    Table 67. AstraZeneca Basic Information, Manufacturing Base and Competitors
    Table 68. AstraZeneca Major Business
    Table 69. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 70. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 71. AstraZeneca Recent Developments/Updates
    Table 72. AstraZeneca Competitive Strengths & Weaknesses
    Table 73. Eli Lily Basic Information, Manufacturing Base and Competitors
    Table 74. Eli Lily Major Business
    Table 75. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 76. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 77. Eli Lily Recent Developments/Updates
    Table 78. Eli Lily Competitive Strengths & Weaknesses
    Table 79. GSK Basic Information, Manufacturing Base and Competitors
    Table 80. GSK Major Business
    Table 81. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 82. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 83. GSK Recent Developments/Updates
    Table 84. GSK Competitive Strengths & Weaknesses
    Table 85. Sanofi Basic Information, Manufacturing Base and Competitors
    Table 86. Sanofi Major Business
    Table 87. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 88. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 89. Sanofi Recent Developments/Updates
    Table 90. Sanofi Competitive Strengths & Weaknesses
    Table 91. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
    Table 92. Bristol-Myers Squibb Major Business
    Table 93. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 94. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 95. Bristol-Myers Squibb Recent Developments/Updates
    Table 96. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
    Table 97. Abbott Laboratories Major Business
    Table 98. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 99. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 100. Global Key Players of Antidiabetic Glucagon-like Peptide 1 Agonists Upstream (Raw Materials)
    Table 101. Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers
    Table 102. Antidiabetic Glucagon-like Peptide 1 Agonists Typical Distributors
List of Figure
    Figure 1. Antidiabetic Glucagon-like Peptide 1 Agonists Picture
    Figure 2. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value and Forecast (2019-2030) & (USD Million)
    Figure 4. World Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030) & (K Units)
    Figure 5. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (2019-2030) & (US$/Unit)
    Figure 6. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share by Region (2019-2030)
    Figure 7. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share by Region (2019-2030)
    Figure 8. North America Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030) & (K Units)
    Figure 9. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030) & (K Units)
    Figure 10. China Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030) & (K Units)
    Figure 11. Japan Antidiabetic Glucagon-like Peptide 1 Agonists Production (2019-2030) & (K Units)
    Figure 12. Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 15. World Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Market Share by Region (2019-2030)
    Figure 16. United States Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 17. China Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 18. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 19. Japan Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 20. South Korea Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 21. ASEAN Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 22. India Antidiabetic Glucagon-like Peptide 1 Agonists Consumption (2019-2030) & (K Units)
    Figure 23. Producer Shipments of Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer Revenue ($MM) and Market Share (%): 2023
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Antidiabetic Glucagon-like Peptide 1 Agonists Markets in 2023
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Antidiabetic Glucagon-like Peptide 1 Agonists Markets in 2023
    Figure 26. United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 27. United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. United States Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share 2023
    Figure 30. China Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share 2023
    Figure 31. Rest of World Based Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share 2023
    Figure 32. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 33. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share by Type in 2023
    Figure 34. Exenatied
    Figure 35. Liraglutide
    Figure 36. Lixisenatide
    Figure 37. Albiglutide
    Figure 38. Dulaglutide
    Figure 39. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share by Type (2019-2030)
    Figure 40. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share by Type (2019-2030)
    Figure 41. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2019-2030) & (US$/Unit)
    Figure 42. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 43. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share by Application in 2023
    Figure 44. Hospital
    Figure 45. Pharmacy
    Figure 46. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Market Share by Application (2019-2030)
    Figure 47. World Antidiabetic Glucagon-like Peptide 1 Agonists Production Value Market Share by Application (2019-2030)
    Figure 48. World Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2019-2030) & (US$/Unit)
    Figure 49. Antidiabetic Glucagon-like Peptide 1 Agonists Industry Chain
    Figure 50. Antidiabetic Glucagon-like Peptide 1 Agonists Procurement Model
    Figure 51. Antidiabetic Glucagon-like Peptide 1 Agonists Sales Model
    Figure 52. Antidiabetic Glucagon-like Peptide 1 Agonists Sales Channels, Direct Sales, and Distribution
    Figure 53. Methodology
    Figure 54. Research Process and Data Source

Companies Mentioned

Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories